NCT01691456已完成1 期
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Area under curve(AUC)
研究概览
简要总结
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study.
详细描述
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited, India comparing with that of SINGULAIR® (Montelukast sodium) 4mg oral granules of Merck Sharp & Dohme Ltd., USA in healthy, adult, human subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must fulfill the following criteria to be considered for inclusion into this study.
- •Healthy subjects within the age range of 18 to 50 years.
- •A body mass index between 18.5 to 24.9 Kg/m2
- •Given written informed consent to participate in the study.
- •Absence of disease markers of HIV 1 & 2, hepatitis B & C virus and RPR.
- •Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening.
- •A normal 12-lead ECG.
- •A normal chest X-ray (PA view).
- •Compliance with the requirement of the entire protocol.
- •No history or no evidence of hypersensitivity to Montelukast and to any component of the formulation.
- •No history of gastrointestinal problems (ulcers).
- •No history of significant systemic diseases.
- •No history of psychiatric disorders.
- •No history of allergic rash.
- •No history of addiction to any recreational drug or drug dependence.
- •No donation of blood (one unit or 350 mL) within 90 days prior to study check in.
- •No Participation in any clinical study within the past 90 days.
- •No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in.
- •No history of dehydration from dialThea, vomiting or any other reason within a period of24.0 hours prior to study check-in.
- •No family history of neurological disorders. Not consumed alcohol and xanthine containing food and beverages (chocolates, tea, coffee or cola drink:s), cigarettes and tobacco products, for at least 48.0 hours prior to study check-in.
- •Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Ca1U1abinoids and Barbiturates) in urine during the day of study check-in.
- •Not consumed grapefruit (mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in.
- •Negative alcohol breath analysis during the study check-in.
- •Female volunteers demonstrating a negative pregnancy test.
- •If study volunteer is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- •or is postmenopausal for at least 1 year. or is surgically . sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the study volunteer).
- •Exclusion Criteria The subjects were excluded based on the following criteria.
- •History of seizures.
- •Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study.
- •History of alcohol consumption for more than two units/day (1 unit = 30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48 hours prior to check-in.
- •High caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/beedies/cigars per day) consumption.
- •History of difficulty with donating blood or difficulty in accessibility of veins.
- •An unusual or abnormal diet, for whatever reason e.g. because of fasting due to religious reasons.
排除标准
- 未提供
研究组 & 干预措施
Montelukast Sodium Oral Granules
Experimental
Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
干预措施: Montelukast sodium (Drug)
SINGULAIR
Active Comparator
(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
干预措施: Montelukast sodium (Drug)
结局指标
主要结局
Area under curve(AUC)
时间窗: Pre-dose (0.00) and 0.50, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 20.00 and 24.00 hours post dose.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fed ConditionHealthyNCT01674517Dr. Reddy's Laboratories Limited35
已完成
1 期
Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fed ConditionHealthyNCT01671722Dr. Reddy's Laboratories Limited43
已完成
1 期
Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting ConditionHealthyNCT01888731Dr. Reddy's Laboratories Limited62
已完成
1 期
Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed ConditionHealthyNCT01888263Dr. Reddy's Laboratories Limited32
已完成
1 期
Lamotrigine Extended-Release Tablets 50 mg Under Fed ConditionHealthyNCT01888757Dr. Reddy's Laboratories Limited62